Verana Health Exit Candidate
π¦ Potential exit path:
SPAC, IPO

Select partners: American Academy of Ophthalmology IRIS Registry, American Academy of Neurology Axon Registry, American Urological Association AQUA Registry, Janssen, Komodo Health.
Funding π°
Total $288.8M
Select investors JJDC, Novo Growth, GV, Merck Global Health Innovation Fund, Casdin Capital, Breyer Capital, Define Ventures, Biomatics Capital
Key people π§βπ€βπ§
- Sujay Jadhav, MBA - CEO
- Marc Berger, JD, MBA - COO
- Matthew Roe, MD, MHS - Chief Medical Officer
- Marie-Eve Piche, MBA, MS - CFO
- Hylton Kalvaria, MBA - Chief Business Officer
Highlights β
- The company's CEO, Sujay Jadhav, has a background in data and that's very important in today's world. Its previous roles include the Global Vice President at Oracle's Health Sciences Business Unit and the CEO of cloud-based clinical research platform goBalto.
- Verana is sitting on a pile of data, encompassing 90 million patients and data spanning seven years. And that data is these days considered a gold mine that could help deliver new insights and even lead to drug discoveries.
- Going forward, Verana aims ot expand upon its established AI capabilities with a particular focus on its pioneering use of natural language processing (NLP) to extract insights from unstructured text data in EHR notes. π
- "Verana Health has shown incredible growth in its collaboration with leading pharmaceutical companies and medical societies. The Company has assembled a seasoned management team with deep experience in healthcare, science, and business that will continue to expand real-world evidence into multiple therapeutic areas with its unique and powerful health data platform, VeraQ" - Jeffrey Low, MD, Principal at Novo Growth π
- "Verana Health is solving this critical need by delivering and analyzing proprietary, curated data sets (Qdata), from both structured and unstructured data that maintain truth to original clinical context. The company is well-positioned to help healthcare providers advance quality care standards, and life sciences companies accelerate clinical research and bring products to market that benefit both patients and physicians." - David W. Parke II, MD, CEO of the American Academy of Ophthalmology π
Last update: February 7, 2022
Disclaimer: We can not guarantee that the information on this page is 100% correct. more